Latest From Sygnis AG
As companies flurried to clinch deals by the end of the year, a number of significant agreements were signed or completed last December.
While Dietmar Hopp clearly had a Midas touch when it came to investing in technology, the billionaire SAP founder has not had the same luck in the life sciences. Strategic changes will have to be on the cards at Wilex and Sygnis Pharma, two of dievini Hopp BioTech's leading portfolio companies.
It's not easy to raise large sums of cash for biotech drug development these days, so having software billionaire Dietmar Hopp on side is an enviable position to be in. And despite the recent blow to his portfolio dealt by the late-stage failure of Agennix's talactoferrin (scripintelligence.com, 7 August 2012), his commitment to biotech is "unwavering", according to one of the key curators of his biotech portfolio, Dr Friedrich von Bohlen. Today's announcement by CureVac would appear to demonstrate this.
The German company Sygnis Pharma expects clinical data from its Phase II study of its G-CSF product, AX200, in acute ischaemic stroke, to be available in the middle of 2011.
Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Sygnis Pharma AG
- Lion bioscience AG
- Western Europe
- Parent & Subsidiaries
- Sygnis AG
- Senior Management
Heikki Lanckriet, PhD, CEO, CSO
David Roth, PhD, CFO
- Contact Info
Phone: (49) 6221 3540 120
Waldhofer Str. 102
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.